- Home
- AGIO vs GBX Comparison
AGIO vs GBX Comparison
Compare AGIO & GBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- GBX
- Stock Information
- Founded
- AGIO 2007
- GBX 1974
- Country
- AGIO United States
- GBX United States
- Employees
- AGIO N/A
- GBX N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- GBX Railroads
- Sector
- AGIO Health Care
- GBX Industrials
- Exchange
- AGIO Nasdaq
- GBX Nasdaq
- Market Cap
- AGIO 2.0B
- GBX 1.8B
- IPO Year
- AGIO 2013
- GBX N/A
- Fundamental
- Price
- AGIO $30.28
- GBX $51.42
- Analyst Decision
- AGIO Buy
- GBX Hold
- Analyst Count
- AGIO 8
- GBX 3
- Target Price
- AGIO $56.57
- GBX $64.00
- AVG Volume (30 Days)
- AGIO 637.9K
- GBX 379.5K
- Earning Date
- AGIO 05-01-2025
- GBX 04-08-2025
- Dividend Yield
- AGIO N/A
- GBX 2.31%
- EPS Growth
- AGIO N/A
- GBX 73.06
- EPS
- AGIO 11.64
- GBX 5.73
- Revenue
- AGIO $36,498,000.00
- GBX $3,611,800,000.00
- Revenue This Year
- AGIO $50.61
- GBX $2.49
- Revenue Next Year
- AGIO $223.79
- GBX $2.20
- P/E Ratio
- AGIO $2.60
- GBX $9.07
- Revenue Growth
- AGIO 36.07
- GBX N/A
- 52 Week Low
- AGIO $27.14
- GBX $41.40
- 52 Week High
- AGIO $62.58
- GBX $71.06
- Technical
- Relative Strength Index (RSI)
- AGIO 39.54
- GBX 36.25
- Support Level
- AGIO $30.00
- GBX $53.50
- Resistance Level
- AGIO $32.90
- GBX $55.12
- Average True Range (ATR)
- AGIO 1.22
- GBX 1.33
- MACD
- AGIO -0.08
- GBX 0.16
- Stochastic Oscillator
- AGIO 9.12
- GBX 7.74
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.